Cardiovascular morbidity in Kyrgyz Republic swung sharply across 2018 to 2024
Diseases of the circulatory system remained a dominant driver of morbidity and mortality in the Kyrgyz Republic, with national surveillance data showing marked fluctuation in both primary incidence and prevalence from 2018 through 2024. The pattern was not smooth. It moved in abrupt waves, with a pronounced rise in 2022 after a period of decline in 2020 and 2021. Those shifts point to a health system that was not operating at a steady baseline, especially during the years shaped by the COVID-19 pandemic, when access to routine care, diagnostic follow-up, and chronic disease management likely changed in meaningful ways.
The analysis covered adults and adolescents and focused on major nosological forms of cardiovascular disease. Official data from the Center for E-Health Care were examined using retrospective, statistical, and comparative analytical methods. The resulting picture places hypertension, coronary heart disease, and cerebrovascular disease at the top of the national burden. These are not isolated diagnoses. They are the core clinical pathway through which long-term vascular injury progresses toward myocardial infarction, stroke, heart failure, and premature death.
A single year stood out.
The 2022 surge points to disrupted detection and delayed care
The most striking feature in the national trend was the greatest increase in both morbidity and prevalence in 2022. That kind of jump rarely reflects biology alone. It often signals a combination of factors: delayed presentation, backlog in outpatient evaluation, improved case finding after care pathways reopen, and a population that has been living with untreated or undertreated vascular risk for months or years. During the pandemic period, reduced access to clinics can suppress reported incidence even as underlying disease continues to advance. When care resumes, the data often rebound sharply, not because disease suddenly appears, but because it is finally being recognized.
This is especially relevant for blood pressure-related disease. Hypertension is often silent until the damage is advanced. When screening drops, the first measurable consequence may be a later wave of diagnosis. The same dynamic can apply to stable coronary heart disease, where chest pain may be minimized or ignored until formal evaluation becomes available again. For cerebrovascular disease, the cost of delayed control is even more direct: poorly managed vascular risk accelerates both large-vessel and small-vessel injury, increasing the probability of stroke and transient ischemic events.
Hypertension, coronary disease, and stroke remained the dominant clinical burden
The highest levels of morbidity and prevalence were consistently concentrated in hypertension, coronary heart disease, and cerebrovascular disease. This distribution fits the usual cascade of cardiovascular pathology. Elevated arterial pressure injures the vascular endothelium, stiffens vessels, and increases left ventricular workload. Over time, that process feeds coronary atherosclerosis and cerebral vessel disease, making the burden of one diagnosis inseparable from the others. A population with broad hypertension prevalence will almost inevitably carry a large burden of ischemic heart disease and stroke unless prevention is aggressive and sustained.
In practical terms, these data argue for a public health strategy that does not treat cardiovascular disease as a single monolith. Screening for blood pressure alone is not enough. Risk reduction has to reach beyond diagnosis to consistent treatment, medication adherence, follow-up, and early identification of people already moving toward symptomatic disease. The national pattern also suggests that secondary prevention may be underpowered. If the surveillance system is capturing a substantial prevalence of established disease while incidence continues to rise in some categories, then control of known cases is not preventing progression at a sufficient scale.
Sharp increases in myocardial infarction and peripheral vascular disease raise concern
Some nosologies, including myocardial infarction and other peripheral vascular diseases, showed sharp increases in indicators. Those changes deserve attention because they are less easily explained by routine chronic disease fluctuation. Myocardial infarction generally reflects a more advanced stage of vascular injury, where plaque instability, thrombosis, and inadequate risk factor control converge. A visible increase in its reported indicators can mean better detection, but it can also mean more acute events reaching the health system after earlier gaps in care.
Peripheral vascular disease tells a similar story from a different vascular bed. It often develops quietly, driven by the same atherosclerotic forces that affect the coronary and cerebral arteries. When its indicators rise, the underlying message is usually systemic: vascular injury is being detected later, and high-risk patients are moving through the disease course without enough early intervention. In settings where access to care is uneven, these diagnoses tend to surface only after symptoms become difficult to ignore.
The study design does not allow separation of true incidence from improved ascertainment in every category. It does, however, show a national cardiovascular profile that changed materially over time and did so in parallel with broader disruptions in health service access.
Monitoring and prevention need to reach high-risk groups sooner
The findings support a stronger system of monitoring, prevention, and early detection for cardiovascular disease in the Kyrgyz Republic, with special attention to high-risk groups. That need is not abstract. It starts with identifying people who already carry hypertension, diabetes, obesity, smoking exposure, or prior vascular events, then ensuring that they remain in continuous care rather than drifting in and out of the system. Population-level surveillance matters, but surveillance alone does not lower stroke or infarction rates unless it is paired with treatment access and follow-up.
The data also reinforce the importance of rebuilding diagnostic continuity after pandemic-related disruption. When routine care is interrupted, the burden of chronic vascular disease does not disappear; it accumulates. Later, it returns as more severe disease, more emergency presentations, and more advanced complications. National indicators from 2018 to 2024 show exactly that kind of volatility, with the steepest climb appearing after the period of reduced activity in 2020 and 2021.
For clinicians and health planners, the implications are concrete. Blood pressure control, ischemic heart disease surveillance, cerebrovascular prevention, and vascular risk assessment need to be embedded in routine care rather than reserved for late-stage disease. The study leaves one central challenge in place: whether future surveillance can distinguish more cleanly between recovery of missed diagnoses and a true increase in cardiovascular event burden. Until that is clearer, the safest interpretation is that the country is still carrying a heavy and uneven cardiovascular load.